Chemomab Therapeutics Ltd.
nebokitug
primary sclerosing cholangitis (PSC)
Date
TBD
Advisory committee · Date TBD estimated
What's at stake
An FDA advisory committee reviews nebokitug for primary sclerosing cholangitis (PSC) around Date TBD. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 6-K
verified 12h ago
“Chemomab announced the successful completion of its End-of-Phase 2 Meeting with the U.S. Food and Drug Administration (FDA) and alignment with FDA on the design of a Phase 3 registration study for nebokitug for the treatment of PSC.”